Gyrus shares dip as Johnson & Johnson cuts stock levels
This article was originally published in Clinica
UK device company Gyrus saw its shares dip 13% last week after it announced that the Ethicon division of Johnson & Johnson, whose distribution of Gyrus' arthroscopy surgical device represents 90% of its turnover, would be holding less stock in future. However, Gyrus says that its discussions with another US healthcare company for distribution of its endourology device are at an advanced stage. The radio frequency ablation device can remove parts of an enlarged prostate in benign prostatic hyperplasia and has applications in bladder cancer.
You may also be interested in...
ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.